Human papillomavirus E7 oncoprotein-derived peptide–Human leukocyte antigen class I complex (HPV E7–HLA-I complex)

The Human papillomavirus (HPV) E7 oncoprotein-derived peptide–Human leukocyte antigen (HLA) class I complex is a molecular assembly presented on the surface of cells infected with high-risk HPV or transformed into malignant states. This complex typically consists of an immunodominant peptide, such as the HPV16 E7(11-19) epitope (YMLDLQPET), bound within the groove of an HLA class I molecule, most frequently HLA-A*02:01. Its primary biological function is to serve as a specific ligand for T-cell receptors (TCRs) on CD8+ cytotoxic T lymphocytes, thereby triggering an adaptive immune response against virally infected or cancerous cells. In the context of disease, the constitutive expression of the E7 oncoprotein is essential for the maintenance of HPV-associated malignancies, including cervical, oropharyngeal, and anal cancers. Because E7 is an intracellular protein, this peptide-MHC complex represents one of the few ways the immune system or therapeutic agents can target the oncoprotein. Current drug development efforts focus on engineered TCR-T cell therapies, such as KITE-439 and TSC-200-A0201, which are designed to recognize this specific complex with high avidity. Additionally, TCR-mimic antibodies and therapeutic vaccines are being explored to enhance the recognition and elimination of cells presenting this target. However, therapeutic efficacy can be challenged by tumor immune evasion mechanisms, such as the downregulation of HLA molecules or mutations in B2M.

Other names

HPV16 E7(11-19)/HLA-A*02:01 complexHPV E7 pMHC complexHPV16 E7 peptide-MHC complexE7(11-19)/HLA-A*02:01

T-cell receptor (TCR) mediated recognition and cytotoxic T-lymphocyte (CTL) activation leading to tumor cell lysis